As shown in Figure 1, both drugs were able to down-regulate survivin expression in all cell lines investigated, which included cells derived from glioblastoma, lymphoma, multiple myeloma, and carcinoma of the breast, colon, and prostate. This evidence concerns the gene BIRC5 and breast carcinoma.